1 – 10 of 14
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Therapeutic S100A8/A9 inhibition reduces NADPH oxidase expression, reactive oxygen species production and NLRP3 inflammasome priming in the ischemic myocardium
- Contribution to journal › Article
-
Mark
Progenitor exhausted PD-1+ T cells are cellular targets of immune checkpoint inhibition in atherosclerosis
(2025) In Nature Cardiovascular Research
- Contribution to journal › Article
- 2024
-
Mark
Reply to “Potential confounders in linking elevated S100A8/A9 to left ventricular dysfunction in septic shock patients”
- Contribution to journal › Letter
-
Mark
Short-term S100A8/A9 Blockade Promotes Cardiac Neovascularization after Myocardial Infarction
(2024) In Journal of Cardiovascular Translational Research
- Contribution to journal › Article
-
Mark
Interleukin-1 receptor accessory protein blockade limits the development of atherosclerosis and reduces plaque inflammation
- Contribution to journal › Article
-
Mark
Mechanistic and therapeutic studies in cardiac inflammation
(2024) In Lund University, Faculty of Medicine Doctoral Dissertation Series
- Thesis › Doctoral thesis (compilation)
-
Mark
IL1RAP Blockade with a Monoclonal Antibody Reduces Cardiac Inflammation and Preserves Heart Function in Viral and Autoimmune Myocarditis
- Contribution to journal › Article
- 2023
-
Mark
S100A8/A9 is a valuable biomarker and treatment target to detect and modulate neutrophil involvement in myocardial infarction
- Contribution to journal › Article
-
Mark
Vascular smooth muscle–specific YAP/TAZ deletion triggers aneurysm development in mouse aorta
- Contribution to journal › Article
-
Mark
Therapeutic S100A8/A9 blockade inhibits myocardial and systemic inflammation and mitigates sepsis-induced myocardial dysfunction
- Contribution to journal › Article
